Could Hormone Therapy Help Tirzepatide Work Better After Menopause?

By Dr David LaMond, Medical Director Blue Sky MD

New research is strengthening the case that menopausal hormone therapy may support a better weight-loss response to tirzepatide in appropriately selected postmenopausal women—a pattern that is also consistent with what we observe in our office.

In a Mayo Clinic study of 120 postmenopausal women with overweight or obesity, researchers compared 40 women using systemic hormone therapy with 80 matched women who were not. All participants had taken tirzepatide for at least 12 months.

At the last follow-up, women using both treatments had lost an average of 19.2% of their initial body weight, compared with 14.0% among women using tirzepatide alone. That is a clinically meaningful difference of 5.2 percentage points—described by the researchers as approximately 35% greater weight loss.

Women using hormone therapy were also substantially more likely to reach a major weight-loss milestone:

• 45% lost at least 20% of their initial body weight.
• Only 18% of women using tirzepatide alone reached that level.

Both groups experienced improvements in metabolic health. Women using hormone therapy also had significant reductions from baseline in diastolic blood pressure, triglycerides, and the liver enzyme AST.

Why might hormone therapy make a difference?

Estrogen affects several systems involved in metabolic health, including insulin sensitivity, fat distribution, energy expenditure, sleep, and appetite regulation. Treating disruptive menopause symptoms may also improve sleep, energy, physical activity, and a patient’s ability to maintain the habits that support long-term weight management.

Hormone therapy is not a stand-alone weight-loss medication, but it may help create a more favorable hormonal and metabolic environment in which treatments such as tirzepatide can work more effectively.

This possibility is supported by an earlier Mayo Clinic study involving semaglutide. In that study, postmenopausal women using hormone therapy lost an average of 16% of their body weight after 12 months, compared with 12% among women who were not using hormone therapy. Finding the same association with both semaglutide and tirzepatide suggests that this may represent a broader and clinically relevant pattern across incretin-based therapies.

What should our patients take away?

These findings reflect what we often see in clinical practice: weight management after menopause is not simply a matter of eating less or exercising more. Hormonal changes, sleep disruption, loss of muscle, insulin resistance, and changes in body-fat distribution can all influence how a patient feels and how she responds to treatment.

For the right patient, addressing menopause symptoms and metabolic health together may produce better results than treating either issue in isolation. Hormone therapy and GLP-1–based treatment should therefore be part of the same thoughtful, individualized clinical conversation.

Because the Mayo Clinic studies were retrospective, they cannot yet prove that hormone therapy directly caused the additional weight loss. Other differences between hormone-therapy users and non-users may have contributed to the results. Prospective randomized trials are still needed.

Even with that limitation, the signal is encouraging, consistent across two medications, biologically plausible, and aligned with what we observe in our office.

Here’s a summary, in plain English

Menopause can make weight harder to manage, even when you’re doing everything right with diet and exercise. New research points to one reason why: hormonal changes may affect how well your body responds to weight-loss medications like tirzepatide.

In a recent study, postmenopausal women who combined tirzepatide with hormone therapy lost about 19% of their body weight, compared to 14% for women on tirzepatide alone. Nearly half reached the 20% weight-loss milestone, compared to fewer than 1 in 5 women not using hormone therapy.

Why the difference? Estrogen plays a role in how your body manages insulin, stores fat, and regulates appetite. It can also improve sleep and energy, which makes it easier to stick with the habits that support long-term weight management.

Hormone therapy isn’t a weight-loss drug on its own, and it isn’t the right fit for every patient. But for women who already have a reason to consider hormone therapy, pairing it with a GLP-1 medication like tirzepatide may lead to better results than either treatment alone.

Curious whether this approach makes sense for you? We’re happy to talk it through at your next visit.

Contact us today to learn more about hormone therapy or GLP-1 medications and how we combine the two. Or, get started with a quick health assessment to see if you qualify for Hormone Replacement Therapy or our medical weight loss program that includes GLP-1.